M&A Deal Summary

Kiromic Acquires InSilico Solutions

On July 26, 2021, Kiromic acquired medical products company InSilico Solutions

Acquisition Highlights
  • This is Kiromic’s 1st transaction in the Medical Products sector.
  • This is Kiromic’s 1st transaction in the United States.
  • This is Kiromic’s 1st transaction in Virginia.

M&A Deal Summary
Date 2021-07-26
Target InSilico Solutions
Sector Medical Products
Buyer(s) Kiromic
Deal Type Add-on Acquisition

Target

InSilico Solutions

Fairfax, Virginia, United States
InSilico Solutions is a bioinformatics company with a stellar track record of developing innovative software for cancer researchers. InSilico's skills in machine learning, modeling, visualization, and intuitive interface design allow presenting complex data to researchers in an interpretable fashion, laying the groundwork for faster and more thorough discovery. InSilico Solutions was founded in 2007 and is based in Fairfax, Virginia.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Kiromic

Houston, Texas, United States
Category Company
Founded 2006
Sector Life Science
Employees19
DESCRIPTION

Kiromic is an immuno-oncology, target discovery, and gene editing company developing highly effective and safe tumor-specific cancer engineered immunotherapies to face and defeat multiple cancer types. The company focused on extending the benefits of immunotherapy by leveraging Diamond AI (Kiromic Diamond Artificial Intelligence), which is a multi-purpose computational platform that can identify new cancer immunological targets for T-Cells and B-Cells. Kiromic was founded in 2006 and is based in Houston, Texas.

DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Virginia) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Mergr

Product

Company

Legal